146 related articles for article (PubMed ID: 38265632)
1. Endosomal protein expression of γ1-adaptin is associated with tumor growth activity and relapse-free survival in breast cancer.
Hoshi N; Uemura T; Tachibana K; Abe S; Murakami-Nishimagi Y; Okano M; Noda M; Saito K; Kono K; Ohtake T; Waguri S
Breast Cancer; 2024 Mar; 31(2):305-316. PubMed ID: 38265632
[TBL] [Abstract][Full Text] [Related]
2. Gamma-adaptin interacts directly with Rabaptin-5 through its ear domain.
Shiba Y; Takatsu H; Shin HW; Nakayama K
J Biochem; 2002 Mar; 131(3):327-36. PubMed ID: 11872161
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of novel clathrin adaptor-related proteins.
Takatsu H; Sakurai M; Shin HW; Murakami K; Nakayama K
J Biol Chem; 1998 Sep; 273(38):24693-700. PubMed ID: 9733768
[TBL] [Abstract][Full Text] [Related]
4. Two Functional Variants of AP-1 Complexes Composed of either γ2 or γ1 Subunits Are Independently Required for Major Histocompatibility Complex Class I Downregulation by HIV-1 Nef.
Tavares LA; de Carvalho JV; Costa CS; Silveira RM; de Carvalho AN; Donadi EA; daSilva LLP
J Virol; 2020 Mar; 94(7):. PubMed ID: 31915283
[TBL] [Abstract][Full Text] [Related]
5. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
6. γ2 and γ1AP-1 complexes: Different essential functions and regulatory mechanisms in clathrin-dependent protein sorting.
Zizioli D; Geumann C; Kratzke M; Mishra R; Borsani G; Finazzi D; Candiello E; Schu P
Eur J Cell Biol; 2017 Jun; 96(4):356-368. PubMed ID: 28372831
[TBL] [Abstract][Full Text] [Related]
7. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis.
Nishimura R; Osako T; Okumura Y; Tashima R; Toyozumi Y; Arima N
World J Surg Oncol; 2011 Oct; 9():131. PubMed ID: 22004841
[TBL] [Abstract][Full Text] [Related]
8. A novel subtype of AP-1-binding motif within the palmitoylated trans-Golgi network/endosomal accessory protein Gadkin/gamma-BAR.
Maritzen T; Schmidt MR; Kukhtina V; Higman VA; Strauss H; Volkmer R; Oschkinat H; Dotti CG; Haucke V
J Biol Chem; 2010 Feb; 285(6):4074-4086. PubMed ID: 19965873
[TBL] [Abstract][Full Text] [Related]
9. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Iorfida M; Mazza M; Balduzzi A; Veronesi P; Luini A; Intra M; Goldhirsch A; Colleoni M
Ann Oncol; 2013 Mar; 24(3):661-8. PubMed ID: 23022996
[TBL] [Abstract][Full Text] [Related]
10. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
11. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
12. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
13. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
[TBL] [Abstract][Full Text] [Related]
14. gamma2-Adaptin, a ubiquitin-interacting adaptor, is a substrate to coupled ubiquitination by the ubiquitin ligase Nedd4 and functions in the endosomal pathway.
Rost M; Döring T; Prange R
J Biol Chem; 2008 Nov; 283(46):32119-30. PubMed ID: 18772139
[TBL] [Abstract][Full Text] [Related]
15. Gamma-BAR, a novel AP-1-interacting protein involved in post-Golgi trafficking.
Neubrand VE; Will RD; Möbius W; Poustka A; Wiemann S; Schu P; Dotti CG; Pepperkok R; Simpson JC
EMBO J; 2005 Mar; 24(6):1122-33. PubMed ID: 15775984
[TBL] [Abstract][Full Text] [Related]
16. mu1A-adaptin-deficient mice: lethality, loss of AP-1 binding and rerouting of mannose 6-phosphate receptors.
Meyer C; Zizioli D; Lausmann S; Eskelinen EL; Hamann J; Saftig P; von Figura K; Schu P
EMBO J; 2000 May; 19(10):2193-203. PubMed ID: 10811610
[TBL] [Abstract][Full Text] [Related]
17. Expression of HER2 and its association with AP-2 in breast cancer.
Pellikainen J; Naukkarinen A; Ropponen K; Rummukainen J; Kataja V; Kellokoski J; Eskelinen M; Kosma VM
Eur J Cancer; 2004 Jul; 40(10):1485-95. PubMed ID: 15196531
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
19. CD4 downregulation by the HIV-1 protein Nef reveals distinct roles for the γ1 and γ2 subunits of the AP-1 complex in protein trafficking.
Tavares LA; da Silva EM; da Silva-Januário ME; Januário YC; de Cavalho JV; Czernisz ÉS; Mardones GA; daSilva LL
J Cell Sci; 2017 Jan; 130(2):429-443. PubMed ID: 27909244
[TBL] [Abstract][Full Text] [Related]
20. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
